Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 2a Randomized Study to Evaluate the Safety and Immunogenicity of the 1790GAHB Generalized Modules for Membrane Antigen Vaccine against Shigella sonnei Administered Intramuscularly to Adults from a Shigellosis-Endemic Country.
Obiero CW, Ndiaye AGW, Sciré AS, Kaunyangi BM, Marchetti E, Gone AM, Schütte LD, Riccucci D, Auerbach J, Saul A, Martin LB, Bejon P, Njuguna P, Podda A. Obiero CW, et al. Among authors: ndiaye agw. Front Immunol. 2017 Dec 22;8:1884. doi: 10.3389/fimmu.2017.01884. eCollection 2017. Front Immunol. 2017. PMID: 29375556 Free PMC article.
Booster Vaccination With GVGH Shigella sonnei 1790GAHB GMMA Vaccine Compared to Single Vaccination in Unvaccinated Healthy European Adults: Results From a Phase 1 Clinical Trial.
Launay O, Ndiaye AGW, Conti V, Loulergue P, Sciré AS, Landre AM, Ferruzzi P, Nedjaai N, Schütte LD, Auerbach J, Marchetti E, Saul A, Martin LB, Podda A. Launay O, et al. Among authors: ndiaye agw. Front Immunol. 2019 Mar 8;10:335. doi: 10.3389/fimmu.2019.00335. eCollection 2019. Front Immunol. 2019. PMID: 30906291 Free PMC article. Clinical Trial.
Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults.
Frenck RW Jr, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, Dickey M, Granada JP, Cilio GL, De Ryck I, Necchi F, Suvarnapunya AE, Rossi O, Acquaviva A, Chandrasekaran L, Clarkson KA, Auerbach J, Marchetti E, Kaminski RW, Micoli F, Rappuoli R, Saul A, Martin LB, Podda A. Frenck RW Jr, et al. Among authors: ndiaye agw. EClinicalMedicine. 2021 Aug 13;39:101076. doi: 10.1016/j.eclinm.2021.101076. eCollection 2021 Sep. EClinicalMedicine. 2021. PMID: 34430837 Free PMC article.
GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.
De Ryck I, Sarakinou E, Nakakana U, Cilio GL, Ndiaye A, Vella V, Auerbach J, Granada JP, Conti V, Podda A. De Ryck I, et al. Infect Dis Ther. 2022 Apr;11(2):757-770. doi: 10.1007/s40121-022-00596-x. Epub 2022 Feb 3. Infect Dis Ther. 2022. PMID: 35118580 Free PMC article.
Correction to: GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.
De Ryck I, Sarakinou E, Nakakana U, Cilio GL, Ndiaye A, Vella V, Auerbach J, Granada JP, Conti V, Podda A. De Ryck I, et al. Infect Dis Ther. 2022 Jun;11(3):1313. doi: 10.1007/s40121-022-00634-8. Infect Dis Ther. 2022. PMID: 35435576 Free PMC article. No abstract available.